Kornitzer Capital Management Inc. KS reduced its stake in shares of Charles River Laboratories International Inc. (NYSE:CRL) by 20.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 132,701 shares of the company’s stock after selling 34,182 shares during the period. Kornitzer Capital Management Inc. KS owned approximately 0.28% of Charles River Laboratories International worth $10,940,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. State Street Corp boosted its stake in Charles River Laboratories International by 3.0% in the first quarter. State Street Corp now owns 1,289,582 shares of the company’s stock valued at $97,928,000 after buying an additional 37,420 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Charles River Laboratories International by 8.9% in the first quarter. Renaissance Technologies LLC now owns 950,209 shares of the company’s stock valued at $72,159,000 after buying an additional 77,700 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Charles River Laboratories International by 45.0% in the first quarter. Goldman Sachs Group Inc. now owns 545,510 shares of the company’s stock valued at $41,426,000 after buying an additional 169,376 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Charles River Laboratories International by 7.0% in the first quarter. Panagora Asset Management Inc. now owns 399,468 shares of the company’s stock valued at $30,336,000 after buying an additional 26,165 shares in the last quarter. Finally, Pembroke Management LTD boosted its stake in Charles River Laboratories International by 5.3% in the second quarter. Pembroke Management LTD now owns 317,435 shares of the company’s stock valued at $26,169,000 after buying an additional 16,000 shares in the last quarter. Institutional investors and hedge funds own 96.19% of the company’s stock.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International Inc. (NYSE:CRL) traded down 0.44% on Friday, hitting $80.55. The stock had a trading volume of 213,545 shares. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 27.21 and a beta of 1.14. Charles River Laboratories International Inc. has a 1-year low of $63.68 and a 1-year high of $89.18. The company has a 50-day moving average price of $82.18 and a 200-day moving average price of $82.89.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 3rd. The company reported $1.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.10. The business earned $434.10 million during the quarter, compared to analyst estimates of $425.05 million. Charles River Laboratories International had a return on equity of 25.18% and a net margin of 9.49%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.96 EPS. Equities analysts predict that Charles River Laboratories International Inc. will post $4.46 earnings per share for the current year.

Several equities research analysts recently weighed in on CRL shares. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Credit Suisse Group AG reaffirmed a “neutral” rating on shares of Charles River Laboratories International in a research report on Friday, September 30th. Citigroup Inc. upped their price objective on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Evercore ISI reissued a “hold” rating and issued a $91.50 target price (up previously from $83.50) on shares of Charles River Laboratories International in a report on Thursday, August 4th. Finally, Jefferies Group increased their target price on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $85.96.

In other Charles River Laboratories International news, insider Davide Molho sold 7,877 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $84.10, for a total transaction of $662,455.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard F. Wallman sold 7,740 shares of Charles River Laboratories International stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $88.00, for a total value of $681,120.00. Following the transaction, the director now directly owns 24,190 shares of the company’s stock, valued at approximately $2,128,720. The disclosure for this sale can be found here. Company insiders own 2.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.